PD-L1 Expression in Triple-Negative Breast Cancer
Mayo Clinic · The University of Texas MD Anderson Cancer Center
Abstract
Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1 (PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine whether PD-L1 is overexpressed in triple-negative breast cancer (TNBC) and to investigate the loss of PTEN as a mechanism of PD-L1 regulation. The Cancer Genome Atlas (TCGA) RNA sequencing data showed significantly greater expression of the PD-L1 gene in TNBC (n = 120) compared with non-TNBC (n = 716; P
Citation impact
- FWCI
- 30.43
- Percentile
- 100%
- References
- 39
Authors
17- EAElizabeth A. MittendorfCorresponding
Mayo Clinic, The University of Texas MD Anderson Cancer Center
- AVAnne V. Philips
Mayo Clinic, The University of Texas MD Anderson Cancer Center
- FMFunda Meric‐Bernstam
Mayo Clinic, The University of Texas MD Anderson Cancer Center
- NQNa Qiao
Mayo Clinic, The University of Texas MD Anderson Cancer Center
- YWYun Wu
Mayo Clinic, The University of Texas MD Anderson Cancer Center
Topics & keywords
- PTEN
- Cancer research
- Small hairpin RNA
- PI3K/AKT/mTOR pathway
- Gene knockdown
- Triple-negative breast cancer
- Biology
- Protein kinase B
- Good health and well-being